Zacks: Analysts Anticipate NanoString Technologies Inc (NSTG) Will Post Earnings of -$0.63 Per Share
Wall Street brokerages expect NanoString Technologies Inc (NASDAQ:NSTG) to announce earnings per share of ($0.63) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for NanoString Technologies’ earnings, with the highest EPS estimate coming in at ($0.53) and the lowest estimate coming in at ($0.71). NanoString Technologies posted earnings of ($0.45) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 40%. The firm is scheduled to issue its next earnings report after the market closes on Thursday, November 8th.
On average, analysts expect that NanoString Technologies will report full-year earnings of ($2.64) per share for the current fiscal year, with EPS estimates ranging from ($2.76) to ($2.54). For the next financial year, analysts anticipate that the business will post earnings of ($2.10) per share, with EPS estimates ranging from ($2.68) to ($1.60). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow NanoString Technologies.
NanoString Technologies (NASDAQ:NSTG) last announced its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.09). The company had revenue of $25.00 million for the quarter, compared to the consensus estimate of $25.10 million. NanoString Technologies had a negative return on equity of 201.90% and a negative net margin of 54.34%.
Shares of NASDAQ:NSTG opened at $15.76 on Wednesday. The firm has a market cap of $531.12 million, a P/E ratio of -8.57 and a beta of 0.46. The company has a debt-to-equity ratio of 5.77, a current ratio of 2.49 and a quick ratio of 2.01. NanoString Technologies has a 12-month low of $5.87 and a 12-month high of $18.86.
In other news, SVP Mary Tedd Allen sold 26,895 shares of NanoString Technologies stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $17.60, for a total value of $473,352.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Nicholas Galakatos sold 85,823 shares of NanoString Technologies stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $15.99, for a total value of $1,372,309.77. The disclosure for this sale can be found here. Company insiders own 20.90% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. grew its stake in shares of NanoString Technologies by 3,422.3% in the 1st quarter. JPMorgan Chase & Co. now owns 156,214 shares of the biotechnology company’s stock valued at $1,173,000 after buying an additional 151,779 shares during the period. ARK Investment Management LLC grew its stake in shares of NanoString Technologies by 17.5% in the 2nd quarter. ARK Investment Management LLC now owns 2,625,472 shares of the biotechnology company’s stock valued at $35,916,000 after buying an additional 391,070 shares during the period. Algert Global LLC grew its stake in shares of NanoString Technologies by 8.4% in the 2nd quarter. Algert Global LLC now owns 222,902 shares of the biotechnology company’s stock valued at $3,049,000 after buying an additional 17,290 shares during the period. Platinum Investment Management Ltd. grew its stake in shares of NanoString Technologies by 66.0% in the 1st quarter. Platinum Investment Management Ltd. now owns 200,800 shares of the biotechnology company’s stock valued at $1,508,000 after buying an additional 79,800 shares during the period. Finally, Metropolitan Life Insurance Co. NY acquired a new stake in shares of NanoString Technologies in the 2nd quarter valued at about $108,000. 73.34% of the stock is owned by hedge funds and other institutional investors.
NanoString Technologies Company Profile
NanoString Technologies, Inc provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files.
Featured Article: Momentum Indicator: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NanoString Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies and related companies with MarketBeat.com's FREE daily email newsletter.